Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernhard C Lechtenberg

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
ACS Medicinal Chemistry Letters|July 26, 2017
Structure-Guided Strategy for the Development of Potent Bivalent ERK InhibitorsBernhard C Lechtenberg, Peter D Mace, E Hampton Sessions, et al.
ACS Medicinal Chemistry Letters|September 24, 2016
Modifications of a Nanomolar Cyclic Peptide Antagonist for the EphA4 Receptor To Achieve High Plasma StabilityErika J Olson, Bernhard C Lechtenberg, Chunxia Zhao, et al.
The Journal of Biological Chemistry|June 17, 2021
A cancer mutation promotes EphA4 oligomerization and signaling by altering the conformation of the SAM domainTaylor P Light, Maricel Gomez-Soler, Zichen Wang, et al.
European Journal of Medicinal Chemistry|November 4, 2024
Lipidation and PEGylation strategies to prolong the in vivo half-life of a nanomolar EphA4 receptor antagonistMaricel Gomez-Soler, Erika J Olson, Elena Rubio de la Torre, et al.
Life Science Alliance|April 1, 2025
The RBR E3 ubiquitin ligase HOIL-1 can ubiquitinate diverse non-protein substrates in vitroXiangyi S Wang, Jenny Jiou, Anthony Cerra, et al.
European Journal of Medicinal Chemistry|March 25, 2024
Lipidation and PEGylation Strategies to Prolong the <i>in Vivo</i> Half-Life of a Nanomolar EphA4 Receptor AntagonistMaricel Gomez-Soler, Erika J Olson, Elena Rubio de la Torre, et al.
Nature Communications|June 19, 2023
Structural mapping of PEAK pseudokinase interactions identifies 14-3-3 as a molecular switch for PEAK3 signalingMichael J Roy, Minglyanna G Surudoi, Ashleigh Kropp, et al.
Redox Biology|December 6, 2022
Design and characterization of a heterobifunctional degrader of KEAP1Hao Chen, Nghi H Nguyen, Charlene M Magtoto, et al.
Nature|April 22, 2026
Ubiquitination of glycogen and metabolites in cells and tissuesMarco Jochem, Simon A Cobbold, Craig A Goodman, et al.
Frontiers in Chemistry|May 2, 2022
Insights Into Drug Repurposing, as Well as Specificity and Compound Properties of Piperidine-Based SARS-CoV-2 PLpro InhibitorsDale J Calleja, Nathan Kuchel, Bernadine G C Lu, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
ACS Medicinal Chemistry Letters|July 26, 2017
Structure-Guided Strategy for the Development of Potent Bivalent ERK InhibitorsBernhard C Lechtenberg, Peter D Mace, E Hampton Sessions, et al.
ACS Medicinal Chemistry Letters|September 24, 2016
Modifications of a Nanomolar Cyclic Peptide Antagonist for the EphA4 Receptor To Achieve High Plasma StabilityErika J Olson, Bernhard C Lechtenberg, Chunxia Zhao, et al.
The Journal of Biological Chemistry|June 17, 2021
A cancer mutation promotes EphA4 oligomerization and signaling by altering the conformation of the SAM domainTaylor P Light, Maricel Gomez-Soler, Zichen Wang, et al.
European Journal of Medicinal Chemistry|November 4, 2024
Lipidation and PEGylation strategies to prolong the in vivo half-life of a nanomolar EphA4 receptor antagonistMaricel Gomez-Soler, Erika J Olson, Elena Rubio de la Torre, et al.
Life Science Alliance|April 1, 2025
The RBR E3 ubiquitin ligase HOIL-1 can ubiquitinate diverse non-protein substrates in vitroXiangyi S Wang, Jenny Jiou, Anthony Cerra, et al.
European Journal of Medicinal Chemistry|March 25, 2024
Lipidation and PEGylation Strategies to Prolong the <i>in Vivo</i> Half-Life of a Nanomolar EphA4 Receptor AntagonistMaricel Gomez-Soler, Erika J Olson, Elena Rubio de la Torre, et al.
Nature Communications|June 19, 2023
Structural mapping of PEAK pseudokinase interactions identifies 14-3-3 as a molecular switch for PEAK3 signalingMichael J Roy, Minglyanna G Surudoi, Ashleigh Kropp, et al.
Redox Biology|December 6, 2022
Design and characterization of a heterobifunctional degrader of KEAP1Hao Chen, Nghi H Nguyen, Charlene M Magtoto, et al.
Nature|April 22, 2026
Ubiquitination of glycogen and metabolites in cells and tissuesMarco Jochem, Simon A Cobbold, Craig A Goodman, et al.
Frontiers in Chemistry|May 2, 2022
Insights Into Drug Repurposing, as Well as Specificity and Compound Properties of Piperidine-Based SARS-CoV-2 PLpro InhibitorsDale J Calleja, Nathan Kuchel, Bernadine G C Lu, et al.
Pageof 4